SynthesisDigestive diseases and sciences2026
Proton Pump Inhibitor Use and Risk of Dementia: An Umbrella Review of Systematic Reviews and Meta-Analyses.
Synthesis in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Medication-safety burden of omeprazole in psychiatric inpatients: A retrospective cross-sectional study.The Journal of international medical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical studies about the association between long-term PPI use and dementia have been inconsistent, with systematic reviews and meta-analyses (SR/MA) reaching disparate conclusions.
aimsThis umbrella review of SR/MA-or overview of reviews-attempts to clarify the current understanding of any possible association linking PPI use to dementia.
methodsWe searched EMBASE, MEDLINE, Cochrane Database of Systematic Reviews (CDSR), and ISI Web of Science for fully published SR/MA in English up to June 2024 using controlled vocabulary and text words [(1) proton pump inhibitor and (2) dementia (dementia and mild cognitive impairment, Alzheimer disease)]. SR/MA methodological overall confidence was scored using the AMSTAR-2 tool.
resultsEleven SR/MA published (May 2016-June 2024) described 21 studies (one randomized trial). The number of studies in these SR/MA ranged from 4 to 14. Six of the included SR/MA reported data on Alzheimer's disease. Only one of the high-overall confidence SR/MA significantly associated PPI use with dementia. None of the six SR/MA investigating PPI use and Alzheimer's disease showed a significant association. Significant associations with dementia in subgroup analyses were found in SR/MA for older patients (one of three SR/MA) (Hazard ratio (HR) = 1.39 (1.17;1.65)), long-term PPI use (one of four SR/MA) (HR = 1.28 (1.12; 1.46)), short-term PPI use (one of four SR/MA) (Risk ratio (RR) = 1.62 (1.40-1.86)), when only considering higher quality studies (one of one SR/MA) (RR = 1.54 (1.12; 2.13)), among European populations (one of three SR/MA) (HR = 1.46 (1.23-1.73)), and cohort studies (two of four SR/MA) (RR = 1.36 (1.19; 1.55)), (RR = 1.44 (1.36; 1.52)).
conclusionMost SRs/MAs suggest no link between PPI use and dementia. Given the low certainty of existing evidence, a true causal relationship appears unlikely.
Indexed as
Identifiers
41087608What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.